CorCinch HFrEF Study Evaluating Safety of AccuCinch Ventricular Repair System in Heart Failure Patients SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of enrollment in its CorCinch HFrEF […]
Tag: Ancora
Ancora Heart Announces Positive Safety and Efficacy Data from Study of First-of-Its-Kind Investigational Heart Failure Therapy
SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced results from an interim analysis of heart failure patients treated in the CorCinch FMR study, a U.S. early feasibility study evaluating the safety of the investigational AccuCinch® Ventricular Repair System designed for the […]
Ancora Heart Enrolls First Patient in European Multi-Center Study of First-of-Its-Kind Investigational Heart Failure Therapy
Study will evaluate a percutaneous therapy designed to improve left ventricular function for patients with systolic heart failure SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced the first patient was enrolled in the CorCinch EU study, a European multi-center clinical […]
Ancora Heart Announces Positive Interim Analysis from Study of First-of-Its-Kind Heart Failure Therapy
SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced positive clinical data from the company’s recently expanded U.S. early feasibility study evaluating the safety of the investigational AccuCinch® Ventricular Repair System designed for the treatment of heart failure and functional mitral regurgitation […]
Ancora Heart Announces $17.8 Million Financing for First-of-Its-Kind Therapy for Systolic Heart Failure
SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced the closing of an initial tranche of $17.8 million in a financing round expected to reach $30 million, led by Savitr Capital and other existing investors. Ancora Heart’s AccuCinch® Ventricular Repair System is […]
Ancora Heart Expands Enrollment of U.S. Early Feasibility Study for the AccuCinch System for Left Ventricular Repair
SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced the expansion of the company’s U.S. feasibility study to evaluate the investigational AccuCinch®Ventricular Repair System designed for the treatment of heart failure and functional mitral regurgitation (FMR). Ancora has received approval from […]